HETEROAROMATIC RING DERIVATIVE

• US 20140081025A1
• Filed: 05/08/2012
• Published: 03/20/2014
• Est. Priority Date: 05/10/2011
• Status: Abandoned Application

• Current Assignee: Taisho Pharmaceutical Company Limited (Taisho Pharmaceutical Holdings Company Limited)
• Original Assignee: Taisho Pharmaceutical Company Limited (Taisho Pharmaceutical Holdings Company Limited)
• Inventors: Suzuki, Ryo, Futamura, Aya, Kashiwa, Shuhei, Hattori, Nobutaka, Nozawa, Dai, Ohta, Hiroshi, Araki, Yuko, Abe, Masahito
• Application Number:
  US14/115,933
• Publication Number:
  US 20140081025A1
• Time in Patent Office: Days
• US Class Current: 544/333
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 25/30 for treating abuse or dependence
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 29/02 without antiinflammatory effect
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 5/00 Drugs for disorders of the endocrine system
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: C07D 401/14 containing three or more hetero rings
• CPC Class Codes: C07D 403/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 413/12 : linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 413/14 : containing three or more hetero rings

Abstract

The compound represented by formula (IA)

or a pharmaceutically acceptable salt thereof is based on orexin (OX) receptor antagonist activity, is useful in the treatment and prevention of illnesses including sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependency, Alzheimer'"'"'s disease, Parkinson'"'"'s disease, Huntington'"'"'s chorea, eating disorders, pain, gastrointestinal disease, epilepsy, inflammation, immunological disease, endocrinological related disease, and hypertension.

Claims

1. A heteroaromatic ring derivative represented by formula (IA):

2. The heteroaromatic ring derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein

R⁴ represents a halogen atom;

and

R⁵ represents a hydrogen atom or a halogen atom.

4. The heteroaromatic ring derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein

X represents a nitrogen atom;

R² represents a C_1-6 alkyl group;

R³ represents a triazolyl group or a pyrimidinyl group; and

R⁴ represents a halogen atom.

5. The heteroaromatic ring derivative or a pharmaceutically acceptable salt thereof according to claim 1, wherein

R² represents a methyl group or an ethyl group.

6. A pharmaceutical composition comprising a heteroaromatic ring derivative or a pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.

7. A therapeutic or prophylactic agent for sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer'"'"'s disease, Parkinson'"'"'s disease, Huntington'"'"'s disease, eating disorder, pain, digestive system disease, epilepsy, inflammation, immune related disease, endocrine related disease, or hypertension, wherein the agent comprises a heteroaromatic ring derivative or a pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.

3. A heteroaromatic ring derivative represented by formula (I):